Belenos Therapeutics

Belenos Therapeutics is a biotechnology company specializing in the development of next-generation antibody therapies for immunological and inflammatory diseases, with a primary focus on dermatology. Launched by ARCH Venture Partners, the company was established to advance a pipeline of high-potential assets targeting key biological pathways involved in chronic skin conditions. In June 2024, Belenos was acquired by Galderma to bolster its research and development portfolio, particularly in the treatment of atopic dermatitis. The acquisition integrates Belenos' innovative antibody programs into Galderma's established dermatology platform. The company's lead programs are designed to provide potential first- and best-in-class treatment options for patients suffering from debilitating inflammatory diseases.